Abstract:(20 S)-Ginsenoside Rh2 is a natural saponin derived from Panax ginseng Meyer (P. ginseng), which showed significantly potent anticancer properties. However, its low water solubility and bioavailability strongly restrict its pharmaceutical applications. The aim of current research is to develop a modified (20 S)-Ginsenoside Rh2 formulation with high solubility, dissolution rate and bioavailability by combined computational and experimental methodology. The "PharmSD" model was employed to predict the optimal polymer for (20 S)-Ginsenoside Rh2 solid dispersion formulations. The solubility of (20 S)-Ginsenoside Rh2 in various polymers was assessed, and the optimal ternary solid dispersion was evaluated across different dissolution mediums. Characterization techniques included the Powder X-ray diffraction (PXRD) and Fourier transform infrared spectroscopy (FTIR). Molecular dynamics simulations were employed to elucidate the formation mechanism of the solid dispersion and the interactions among active pharmaceutical ingredient (API) and excipient molecules. Cell and animal experiments were conducted to evaluate the in vivo performance of the modified formulation. The "PharmSD" solid dispersion model identified Gelucire 44/14 as the most effective polymer for enhancing the dissolution rate of Rh2. Subsequent experiment also confirmed that Gelucire 44/14 outperformed the other selected polymers. Moreover, the addition of the third component, sodium dodecyl sulfate (SDS), in the ternary solid dispersion formulation significantly amplified dissolution rates than the binary systems. Characterization experiments revealed that the API existed in an amorphous state and interacted via hydrogen bonding with SDS and Gelucire. Moreover, molecular modeling results provided additional evidence of hydrogen bonding interactions between the API and excipient molecules within the optimal ternary solid dispersion. Cell experiments demonstrated efflux ratio (EfR) of Rh2 ternary solid dispersion was lower than that of pure Rh2. In vivo experiments revealed that the modified formulation substantially improved the absorption of Rh2 in rats. Our research successfully developed an optimal ternary solid dispersion for Rh2 with high solubility, dissolution rate and bioavailability by integrated computational and experimental tools. The combination of Artificial Intelligence (AI) technology and molecular dynamics simulation is a wise way to support the future formulation development.

Three Polymorphs and Two Hydrates of a Multidrug Crystal Involving Gefitinib and Rhein: Characterization, Stability, and Solubility Aspects

“Drug–Coformer–Drug” Multicomponent Crystals to Simultaneously Improve the Solubility of Two Insoluble Combined Drugs by Introduction of a Soluble Coformer

A novel drug-drug cocrystal of tegafur and myricetin: optimized properties of dissolution and tabletability

Impact of Crystal Habit on Solubility of Ticagrelor

Computer-driven formulation development of Ginsenoside Rh2 ternary solid dispersion

Solid amorphous formulations for enhancing solubility and inhibiting Erlotinib crystallization during gastric-to-intestinal transfer

Insight into the Dissolution Molecular Mechanism of Ternary Solid Dispersions by Combined Experiments and Molecular Simulations

A Drug–Drug Cocrystal of Dihydromyricetin and Pentoxifylline

Temozolomide–Hesperetin Drug–Drug Cocrystal with Optimized Performance in Stability, Dissolution, and Tabletability

Cocrystals of regorafenib with dicarboxytic acids: synthesis, characterization and property evaluation

Novel Pharmaceutical Cocrystals of Tegafur: Synthesis, Performance, and Theoretical Studies

Ritonavir Revisited: Melt Crystallization Can Easily Find the Late-Appearing Polymorph II and Unexpectedly Discover a New Polymorph III.

Toltrazuril Polymorphs and the Effect on Hygroscopicity and Dissolution Rate

A Drug–Drug Cocrystal Strategy to Regulate Stability and Solubility: A Case Study of Temozolomide/Caffeic Acid

Characterization, crystal structure and stability analysis of dianhydrodulcitol polymorphs

Tailoring the Particle Microstructures of Gefitinib by Supercritical Co2 Antisolvent Process

Synthon polymorphs of 1 : 1 co-crystal of 5-fluorouracil and 4-hydroxybenzoic acid: their relative stability and solvent polarity dependence of grinding outcomes

Cocrystallization of lenvatinib and temozolomide to improve the performance in terms of stability, dissolution, and tabletability

Polymorphism in Griseofulvin: New Story Between an Old Drug and Polyethylene Glycol

Microcrystalline Cellulose As an Effective Crystal Growth Inhibitor for the Ternary Ibrutinib Formulation.

[Preparation, Characterization and Antitumor of Cyclodextrin Inclusion of an Anti-Cancer Drug Regorafenib].